



Schedule of Pharmaceutical Benefits

for Approved Pharmacists and Medical Practitioners

Effective from 1 November 1998



Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners

OPERATIVE FROM 1 NOVEMBER 1998 (ALL PREVIOUS EDITIONS CANCELLED)

PHARMACEUTICAL BENEFITS

This Schedule will take effect on 1 November 1998 and all previous issues are cancelled. Schedules are published quarterly, i.e., 1 February, 1 May, 1 August and 1 November each year.

Change of Address

Notification of change of address should be directed to the Pharmaceutical Branch, Health Insurance Commission, GPO Box 9826, in your Capital City, or telephone 132 290.

Additional Copies

Additional copies of the Schedule may be purchased from:

J.S. McMillan Outsourcing Dock 8, corner of Derby and Stubbs Streets SILVERWATER NSW 2128 Telephone: (02) 9648 3333 Facsimile: (02) 9648 4209

Section 1 — Explanatory Notes (yellow pages)

Fees and Patient Contributions

The explanatory notes in Section 1 (yellow pages) have been revised in this issue of the Schedule. The notes have been presented in a more logical sequence and in more user-friendly language; however, there have been no changes made to the underlying legislation governing the Pharmaceutical Benefits Scheme.

| | • | | |
|---|---|--|----------------------|
| | The following fees and patient contributions applicable, in prices published it | | 88 and are included, |
| - | Composite (dispensing) fees: | Ready-prepared | \$4.34 |
| ÷ | | Extemporaneously-prepared | \$6.20 |
| | Additional fees (for safety net prices): | Ready-prepared Extemporaneously-prepared | \$0.85 \$1.23 |
| i | | | |
| ÷ | Patient contributions: | General | \$20.00 |
| : | | Concessional | \$3.20 |
| | Safety net thresholds: | General | \$612.60 |

Concessional

\$166.40

SUMMARY OF CHANGES

ADDITIONS

Additions — Items



Additions — Brands

2070V Marsalar 100 mm DM Vaccounide Wasseritusts tablet 100 mm (exertained valorge)

8273K Monodur 120 mg, PM—**Isosorbide Mononitrate**, tablet 120 mg (sustained release)

BIOEQUIVALENCE INDICATORS

The bioequivalence indicator $\binom{a}{1}$ has been added to the following brands:

8273K Imdur 120 mg. AP—**Isosorbide Mononitrate**, tablet 120 mg (sustained release)

| CARDIOVASCULAR SYSTEM —cont. | | | | | | | | |
|------------------------------|---|-------------|---------------|---------------|---|--|--------------------------------------|--|
| Code | Name, Restriction, Manner of administration and form | Max. Qty | No.of Rpts | Premium \$ | Dispensed Price for Max.Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer | |
| | | | | | | | | |
| | | | | | | | | |

AF SW AF SW

AF HX BQ

GW

RR

ML

SR

SR

MM

ro CG

SH

| · 1558B | ISOSORBIDE MONONITRATE Tablet 60 mg (sustained release) | 30 | 5 | | . 16.9 | 9 17.84 | |
|---------|--|----|---|-------------------|--------|---------|---|
| | | | | в 1.38 | 18.3 | 7 17.84 | ^a Monodur 60 mg PM ^a Imdur Durule AP |
| 8273K | Tablet 120 mg (sustained release) | 30 | 5 | | . 24.5 | 8 20.00 | ^a Monodur 120 mg PM |
| | | | | B _{1.38} | 25.9 | 6 20.00 | a Imdur 120 mg AP |

 Monodur 60 mg (PM)
 35

 Monodur 120 mg (PM)
 35